Stephen R Bloom Selected Research

Peptide YY

1/2021	Safety and efficacy of an extended-release peptide YY analogue for obesity: A randomized, placebo-controlled, phase 1 trial.
1/2019	Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study.
11/2015	Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults.
11/2014	Combination of peptide YY3-36 with GLP-1(7-36) amide causes an increase in first-phase insulin secretion after IV glucose.
12/2011	Pancreatic polypeptide meal response may predict gastric band-induced weight loss.
3/2011	Changes in gastrointestinal hormones and leptin after Roux-en-Y gastric bypass surgery.
8/2010	Bowels control brain: gut hormones and obesity.
5/2010	Vagal sparing surgical technique but not stoma size affects body weight loss in rodent model of gastric bypass.
11/2008	Peptide YY: a gut hormone associated with anorexia during infectious diarrhea in children.
2/2008	Can gut hormones control appetite and prevent obesity?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephen R Bloom Research Topics

Disease

71	Obesity 10/2021 - 02/2002
29	Weight Loss (Weight Reduction) 11/2021 - 08/2005
27	Body Weight (Weight, Body) 11/2021 - 02/2002
23	Type 2 Diabetes Mellitus (MODY) 10/2021 - 01/2005
10	Overweight 11/2015 - 08/2005
8	Neoplasms (Cancer) 02/2015 - 06/2004
7	Insulin Resistance 11/2015 - 04/2004
7	AIDS-Related Complex (ARC) 01/2014 - 06/2004
6	Nausea 01/2018 - 08/2006
6	Infertility (Sterility) 06/2016 - 11/2009
6	Anorexia 11/2008 - 10/2003
5	Hyperphagia (Overeating) 04/2014 - 06/2002
5	Prader-Willi Syndrome (Syndrome, Prader-Willi) 10/2008 - 02/2002
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 11/2021 - 02/2016
3	Weight Gain 11/2015 - 01/2006
3	Hyperglycemia 11/2014 - 08/2012
3	Neoplasm Metastasis (Metastasis) 06/2012 - 11/2006
3	Hypertrophy 07/2010 - 09/2007
2	Non-alcoholic Fatty Liver Disease 01/2022 - 01/2019
2	Prediabetic State (Prediabetes) 01/2021 - 01/2019
2	Hypoglycemia (Reactive Hypoglycemia) 01/2021 - 01/2016
2	Pre-Eclampsia (Preeclampsia) 05/2015 - 11/2010
2	Hypogonadism (Hypergonadotropic Hypogonadism) 01/2014 - 11/2012
2	Carcinoma (Carcinomatosis) 06/2012 - 06/2010
2	Morbid Obesity 10/2011 - 09/2011
2	Anemia 03/2010 - 05/2009
2	Malnutrition (Nutritional Deficiencies) 10/2007 - 07/2005
2	Anorexia Nervosa 04/2007 - 04/2005
2	Gestational Trophoblastic Disease (Trophoblastic Neoplasms, Gestational) 03/2007 - 11/2006
2	Hyperinsulinism (Hyperinsulinemia) 05/2005 - 04/2004
1	Hepatocellular Carcinoma (Hepatoma) 01/2022
1	Cicatrix (Scar) 11/2021
1	Body Weight Changes 01/2021
1	Pain (Aches) 01/2020
1	Hypersensitivity (Allergy) 01/2020
1	Chronic Pain 01/2020
1	Metabolic Diseases (Metabolic Disease) 01/2019
1	Epilepsy (Aura) 11/2018

Drug/Important Bio-Agent (IBA)

44	Hormones (Hormone)IBA 01/2021 - 02/2002
30	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2021 - 06/2004
22	GhrelinIBA 01/2014 - 11/2003
17	Peptide YYIBA 01/2021 - 06/2004
16	OxyntomodulinIBA 01/2019 - 12/2002
15	Peptides (Polypeptides)IBA 01/2020 - 06/2004
13	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2005
13	KisspeptinsIBA 06/2016 - 11/2006
12	Insulin (Novolin)FDA Link 01/2019 - 02/2002
11	LeptinIBA 05/2014 - 02/2002
7	Glucagon (Glukagon)FDA Link 01/2022 - 08/2010
5	Glucagon-Like Peptide-1 ReceptorIBA 10/2021 - 01/2018
5	Pancreatic Polypeptide (Pancreatic Polypeptide (PP))IBA 02/2016 - 01/2008
4	Biomarkers (Surrogate Marker)IBA 02/2016 - 12/2011
4	Appetite Depressants (Anorectics)IBA 12/2011 - 06/2004
3	Proglucagon (Glucagon Precursors)IBA 01/2020 - 11/2014
3	Peptide Hormones (Polypeptide Hormones)IBA 01/2017 - 05/2005
3	Gastrointestinal Hormones (Hormones, Gastrointestinal)IBA 02/2016 - 04/2005
3	Cholecystokinin (Pancreozymin)IBA 08/2010 - 12/2007
3	Pro-Opiomelanocortin (Proopiomelanocortin)IBA 02/2010 - 11/2004
2	LigandsIBA 01/2022 - 11/2020
2	CholesterolIBA 01/2022 - 07/2005
2	Glucagon Receptors (Glucagon Receptor)IBA 11/2021 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 11/2021 - 03/2018
2	Liraglutide FDA Link 01/2021 - 01/2019
2	Exenatide (Byetta)FDA Link 03/2018 - 05/2012
2	Inulin FDA Link 01/2017 - 11/2015
2	Phosphotransferases (Kinase)IBA 01/2016 - 11/2014
2	IncretinsIBA 12/2015 - 02/2002
2	Messenger RNA (mRNA)IBA 01/2014 - 08/2005
2	NeuropeptidesIBA 08/2013 - 05/2013
2	Chromogranin AIBA 06/2012 - 05/2012
2	Amphetamine (Amfetamine)FDA LinkGeneric 05/2012 - 04/2008
2	Cocaine (Cocaine HCl)IBA 05/2012 - 04/2008
2	Islet Amyloid PolypeptideIBA 08/2010 - 01/2008
2	Glucagon-Like Peptide 2IBA 07/2010 - 07/2005
2	salicylhydroxamic acid (SHAM)IBA 05/2010 - 05/2010
2	IronIBA 03/2010 - 05/2009
2	HepcidinsIBA 03/2010 - 05/2009
1	Monensin (Coban)IBA 11/2021
1	Wiskott-Aldrich Syndrome ProteinIBA 11/2021
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 10/2021
1	ArrestinsIBA 01/2021
1	Nerve Growth Factor (NGF)IBA 01/2020
1	TRPV1 receptorIBA 01/2020
1	CannabidiolIBA 01/2020
1	Nerve Growth Factors (Neurotrophins)IBA 01/2020
1	Therapeutic UsesIBA 01/2020
1	Glial Cell Line-Derived Neurotrophic Factor (GDNF)IBA 01/2020
1	FructosamineIBA 01/2019
1	Pharmaceutical PreparationsIBA 01/2019
1	2-methylcyclopentadienyl manganese tricarbonyl (MMT)IBA 01/2019
1	Bile Acids and Salts (Bile Acids)IBA 01/2019
1	ClathrinIBA 03/2018

Therapy/Procedure

33	Therapeutics 01/2021 - 07/2003
15	Gastric Bypass (Roux-en-Y Gastric Bypass) 01/2021 - 11/2006
13	Bariatric Surgery 01/2021 - 01/2006
3	Drug Therapy (Chemotherapy) 11/2021 - 03/2007
2	Vagus Nerve Stimulation 11/2018 - 01/2018
2	Subcutaneous Injections 11/2009 - 01/2006
1	Caloric Restriction 01/2021
1	Gastrectomy 01/2019